We're lifting our price target on Cardinal Health after issuing rosy profit guidance
Cardinal Health (CAH) reported fiscal 2026 Q4 results for the three months ended June 30. Revenue rose about 6% to $63.67B, below LSEG’s $65.03B estimate. Adjusted EPS was $2.60 vs $2.42 consensus, excluding a 31-cent tariff-refund benefit. The firm raised its price target to $265 from $245 and kept a hold-equivalent 2 rating.
How this was made
The 30-second read
Why it matters
The key tradable change is the raised price target to $265 alongside guidance that outperformed expectations, which can drive incremental positioning even if the quarter had a revenue shortfall.
Market read
A guidance beat plus an explicit price-target increase is a fresh catalyst for CAH, but investors may reprice risk around Medicare-driven pricing and future contract renegotiations.
What to watch
Future renegotiations tied to Medicare price caps may pressure segment profits even if the fee-for-service model insulates near-term results.
Background
The piece frames Cardinal’s quarter as imperfect on revenue but strong on adjusted profitability, with emphasis on specialty pharmaceuticals and fee-for-service volume economics.
Ticker impact
Cardinal Health reported fiscal 2026 results with adjusted EPS of $2.60 and raised its fiscal 2027 outlook, prompting a price-target lift to $265.
Bullish bias for the next few sessions, with potential volatility if investors focus on the revenue miss and future profit pressure from lower WAC.
The article cites a concrete earnings beat, stronger profitability narrative, and an explicit analyst price-target increase, while also flagging top-line weakness and contract renegotiation sensitivity.
Market effects
Reinforces the view that healthcare distributors can offset drug-price pressure via fee-for-service volume and higher-margin specialty mix.
Primarily US-focused read-through to managed care and Medicare pricing dynamics affecting distribution economics.
Limited, as the drivers cited are US Medicare negotiations and US tariff refund effects.
Counterpoint
The revenue miss and reliance on tariff-refund dynamics could mean the profitability story is less durable than it appears, especially as contracts renew under lower WAC.
Key entities
- companyCardinal Health
Healthcare distributor reporting fiscal 2026 quarter results and raised outlook, leading to a higher analyst price target.
- executiveAaron Alt
CFO quoted discussing GLP-1 revenue visibility and the fee-for-service compensation model.
- executiveJason Hollar
CEO quoted on the company’s role and why compensation should not change despite Medicare WAC dynamics.
